Oncology in Clinical Practice

Strona główna
Polska
Warsaw
Oncology in Clinical Practice

Dane kontaktowe, mapa i wskazówki, formularz kontaktowy, godziny otwarcia, usługi, oceny, zdjęcia, filmy i ogłoszenia od Oncology in Clinical Practice, Zdrowie i medycyna, Ulica Roentgena 5, Warsaw.

24/10/2025

Doxorubicin extravasation is related to a high risk of severe ulceration and necrosis. This case of a 71-year-old female shows that prompt intervention with DMSO (dimethyl sulfoxide) and continuous cooling enabled full recovery—highlighting this effective management strategy.

Authors: Karolina Potemska, Dominik Dubieński, Beata Śniecikowska, Magdalena Sobczak, Sylwia Dębska-Szmich
Available at:
https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/107156

23/10/2025

How effective is everolimus + exemestane after CDK4/6 inhibitor use in hormone receptor-positive metastatic breast cancer?
This real-world study of 69 patients from a UK tertiary cancer centre reports a median progression-free survival (PFS) of 5 months for this treatment combination. Findings highlight the limited efficacy post-CDK inhibition and emphasize the need for alternative strategies.
Authors: Smriti Gaur, Jill Bishop
📖 Read the full article: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106191

21/10/2025

What is the clinical efficacy and safety profile of pyrotinib in metastatic HER2-positive breast cancer patients? This multicentre study of 275 patients reports a 56% response rate and median OS of 35 months, with manageable toxicity.

Authors: Min Gao, Yuhui Li, Qingfen D**g, Fang Chen, Chao Fu, Shuaishuai Liu, Shuai Liu, Xiao Ju, Xin Zheng, Jie Lu
Link to full article in the first comment below ⬇️

20/10/2025

Combination therapies may offer more personalized care for prostate cancer patients.
This review explores how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, chemotherapy, immunotherapy, or radiopharmaceuticals is reshaping survival outcomes and quality of life across disease stages.
Author: Piotr J. Wysocki

16/10/2025

HER2 is a well-known target in breast cancer therapy—but what about other tumors? This review explores advances in anti-HER2 treatments for gastric, lung, colorectal, endometrial, HER2-low breast cancer and other cancers. A comprehensive look at new research directions related to HER2.
Authors: Jan Semeradt, Olaf Krawczyk, Norbert Krawczyk, Piotr Jędrzejczak, Wojciech Kopyciński, Sylwia Dębska-Szmich
📖 Read the full text at: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106480

09/10/2025

How effective is encorafenib + binimetinib (E+B) beyond clinical trials? This multicentre real-world study shows encouraging outcomes across first-, second-, and third-line settings in BRAF-mutant advanced melanoma patients, with ORRs up to 58.5% and median PFS of 10.3 months in first-line therapy.

Authors: Anna M. Czarnecka, Piotr Błoński, Bożena Cybulska-Stopa, Wiesław Bal, Robert Dziura, Magdalena Ciążyńska, Krzysztof Ostaszewski, Katarzyna Krawczak, Łukasz Galus, Katarzyna Kozak, Natasza Kempa-Kamińska, Grażyna Kamińska-Winciorek, Marta Pabianek, Paweł Rogala, Tomasz Kubiatowski, Marcin Ziętek, Jacek Mackiewicz, Piotr Rutkowski

📖 Read the full article: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/107991

06/10/2025

Extra-gastrointestinal stromal tumours (EGISTs) rarely originate in the prostate. This case report of a 61-year-old male describes diagnosis, treatment with radical prostatectomy and adjuvant imatinib, and includes a literature review. A valuable addition to the limited data on prostatic EGISTs.

Authors: Tayyip İlker Aydın, Gökhan Öztürk, Muhammet Bekir Hacıoğlu, Ebru Taştekin, Dicle Tamer Türk, Aykut Alkan, Aysun Fatma Akkuş, İsmail Bayrakçı, Gizem Bakır Kahveci, Didem Divriklioğlu, Dicle Yurdatap Koç, Ece Demirdelen

Full text available at:
https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106439

30/09/2025

Cemiplimab, an anti–PD-1 antibody, offers significant survival benefits in NSCLC. This review summarizes the practical aspects of cemiplimab use in NSCLC patients, according to the current drug program in Poland. Mechanisms of action and resistance are also discussed, along with findings from recent clinical trials such as EMPOWER-Lung 1 and EMPOWER-Lung 3.

Authors: Dariusz M. Kowalski, Ewa Kalinka, Katarzyna Stencel, Kamila Wojas-Krawczyk, Paweł Krawczyk, Adam Płużański, Damian Tworek, Rafał Krenke, Jacek Fijuth, Tadeusz Orłowski, Renata Langfort, Piotr Jaśkiewicz, Wojciech Naumnik, Rodryg Ramlau, Maciej Krzakowski

📖 Read the full text: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106900

17/09/2025

Leukocytoclastic vasculitis is a rare but serious dermatologic toxicity associated with panitumumab in metastatic colorectal cancer. This case report of a 51-year-old man with biopsy-confirmed lesions highlights the importance of early recognition and effective management of such adverse events.

Authors: Oğuzhan Yıldız, Murat Araz, Melek Karakurt Eryılmaz, Ali Fuat Gürbüz, Talat Aykut, Engin Hendem, Fahriye Kılınç, Mehmet Artaç
📖 Full case available at:
https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/104263

15/09/2025

An ingenious analysis aimed to assess the impact of the COVID-19 pandemic on early melanoma diagnosis and treatment by comparing the thickness of melanoma tumours resected in the years before and after the outbreak.

Authors: Monika Dudzisz-Śledź, Magdalena Ciążyńska, Paweł Teterycz, Marta Pabianek, Marcin Zdzienicki, Maria Krotewicz, Monika Kondracka, Piotr Rutkowski
📖 Full text available at: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/104136

11/09/2025

In a cohort of 151 patients treated with immune-checkpoint inhibitors, 38% experienced immune-related adverse events (irAEs), most commonly thyroid dysfunction and dermal toxicity. While organ toxicities did not significantly impact overall or progression-free survival, vigilant toxicity management remains essential to maintain patients’ safety and quality of life during immunotherapy.

📄 Full article available at:
🔗 https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/101838

Authors: Anna Rudzińska, Pola Juchaniuk, Jakub Oberda, Kacper Ponikowski, Anna Rodzajewska, Mariola Janiszewska, Katarzyna Machulska-Ciuraj, Katarzyna Szklener

08/09/2025

A rare case of BRAF-negative melanoma of unknown primary presenting as a cardiac tumour.
After challenging diagnostics, the tumour was ultimately identified as melanoma of unknown primary.
Read the full text for a comprehensive description of the diagnostic investigation, treatment course, and literature review:
https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/104774

Authors: Magdalena K. Zielińska, Monika Dudzisz-Śledź, Krzysztof Ostaszewski, Aneta Borkowska, Anna M. Czarnecka

Adres

Ulica Roentgena 5
Warsaw
02-781

Strona Internetowa

https://journals.viamedica.pl/oncology_in_clinical_practice, https://www.researchgate.net/journal/Oncology-in-Clinical-P

Ostrzeżenia

Bądź na bieżąco i daj nam wysłać e-mail, gdy Oncology in Clinical Practice umieści wiadomości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu i możesz zrezygnować z subskrypcji w dowolnym momencie.

Skontaktuj Się Z Praktyka

Wyślij wiadomość do Oncology in Clinical Practice:

Skróty

Chcesz aby twoja praktyka była na górze listy Klinika w Warsaw?

Udostępnij

Kategoria

Zdrowie i medycyna